Amneal Pharmaceuticals, Inc. Class A Forecast, price target & analysts
Amneal Pharmaceuticals, Inc. Class A Target price 2025 - Analyst rating & recommendation
Amneal Pharmaceuticals, Inc. Class A Classifications & Recommendation:
Amneal Pharmaceuticals, Inc. Class A Price Target
| Target Price | $11.50 |
| Price | $8.88 |
| Potential |
29.50%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target Amneal Pharmaceuticals, Inc. Class A 2026 .
The average Amneal Pharmaceuticals, Inc. Class A target price is $11.50.
This is
29.50%
register free of charge
$12.00
35.14%
register free of charge
$11.00
23.87%
register free of charge
|
|
| A rating was issued by 4 analysts: 4 Analysts recommend Amneal Pharmaceuticals, Inc. Class A to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Amneal Pharmaceuticals, Inc. Class A stock has an average upside potential 2026 of
29.50%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.79 | 2.98 |
| 16.73% | 6.58% | |
| EBITDA Margin | 21.10% | 22.20% |
| 2.55% | 5.22% | |
| Net Margin | -4.21% | 3.33% |
| 32.18% | 179.01% |
3 Analysts have issued a sales forecast Amneal Pharmaceuticals, Inc. Class A 2025 . The average Amneal Pharmaceuticals, Inc. Class A sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Amneal Pharmaceuticals, Inc. Class A EBITDA forecast 2025. The average Amneal Pharmaceuticals, Inc. Class A EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 Amneal Pharmaceuticals, Inc. Class A Analysts have issued a net profit forecast 2025. The average Amneal Pharmaceuticals, Inc. Class A net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.38 | 0.32 |
| 20.83% | 184.21% | |
| P/E | 27.75 | |
| EV/Sales | 1.78 |
3 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast for earnings per share. The average Amneal Pharmaceuticals, Inc. Class A <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Amneal Pharmaceuticals, Inc. Class A stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Amneal Pharmaceuticals, Inc. Class A...
Current Amneal Pharmaceuticals, Inc. Class A Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Oct 02 2024 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Feb 24 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Oct 02 2024 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
